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therapy.  The patient had a routine blood pressure check 
after the chemotherapy infusion and was found to be 
hypotensive at 80/58 mmHg.  He reported increasing 
fatigue over the past week.  He denied chest pain, 
shortness of breath, dizziness and headache.  He was 
given one liter of normal saline solution, but remained 
hypotensive and was directly admitted to the hospital.  
On physical exam, the patient was tachycardic to 102 
beats per minute with a regular rhythm, clear lungs, and 
positive orthostatics.  Laboratory studies were significant 
for a thyroid stimulating hormone  of <0.02 uIU/mL 
(normal range = 0.3 – 5 uIU/mL), free T4 of 1.2 ng/dL 
(normal range = 0.7 – 1.7 ng/dL), follicle stimulating 
hormone of 0.9 mIU/mL (normal range 1.5 – 12.4 mIU/mL), 
adrenocorticotropic hormone (ACTH) of <9 pg/mL (normal 
range 9 – 46 pg/mL), total testosterone of  4 ng/dL (normal 
range 250 – 1100 ng/dL, and a free testosterone of 
0.4 pg/mL (normal range 35 – 155 pg/mL).  His white blood 
cell count, hemoglobin and electrolytes were within 
normal limits.  A noon cortisol was 0.3 mcg/dL (normal 
A.M. range 16 – 20 mcg/dL and P.M. range 2 – 12 mcg/dL) 
InTroduCTIon
Ipilimumab (Yervoy®) is a human monoclonal antibody 
that has been shown to significantly improve survival 
in cases of metastatic melanoma.1  Ipilimumab blocks 
cytotoxic T-lymphocyte antigen 4 (CTLA-4), a protein 
receptor on the surface of T-cells, resulting in their 
activation, proliferation and an anti-tumor response.2,3,4 
Commonly reported immune-related side effects of 
ipilimumab are enterocolitis, dermatitis, and hepatitis.5,6,7  
However, different endocrinopathies, including 
autoimmune hypopituitarism, have become emerging 
clinical entities in patients taking ipilimumab.  We present 
a case of ipilimumab induced hypophysitis in a 62-year- 
old male presenting with fatigue and hypotension. 
CaSE PrESEnTaTIon
A 62-year-old male with a history of melanoma metastatic 
to the lung and brain status-post frontal craniotomy and 
whole brain radiation, as well as a recent diagnosis of 
hypothyroidism, presented from the oncology office with 
hypotension after receiving his fourth dose of ipilimumab 
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Figure 2. Postcontrast T1-weighted magnetic resonance image of 
the brain three months before presentation and prior to starting 
ipilimumab, demonstrating normal pituitary gland architecture 
and size (arrow). 
Figure 1. Postcontrast T1-weighted magnetic resonance image 
of the brain two days prior to the fourth dose of ipilimumab and 
hospital admission, demonstrating diffuse enlargement of the 
pituitary gland (arrow).
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MRI findings in ipilimumab-induced hypophysitis are 
non-specific and are typically characterized by a diffuse 
enlargement and homogeneous enhancement of 
the pituitary gland.  Less commonly, heterogeneous 
enhancement has also been described.10-11  While it is 
common to have radiographic evidence of hypopitu-
itarism, a normal MRI is possible.  Follow-up imaging 
often shows resolution of abnormal findings after 
hormone replacement.11
Pituitary hormone replacement with corticosteroids is 
critical to treatment, assuming ACTH is low.  Either high 
dose or physiologic replacement dose corticosteroids 
are needed.  Current recommendations advocate for 
high dose (1-2 mg/kg/day of prednisone or equivalent) 
steroids for moderate to life threatening symptoms.12 
However, it is not clear whether initial high doses of 
corticosteroids are beneficial in treating hypophysitis. 
While they may play a role in reducing inflammation, they 
do not improve neuro-endocrine function compared 
to physiologic doses.  However, high doses of cortico-
steroids may increase morbidity through side effects.3, 13 
Mineralocorticoid replacement is not needed since the 
renin-angtiotensin-aldosterone system is still intact.  It 
should be at the discretion of the oncologist and endocri-
nologist as to whether ipilimumab should be continued 
based on the condition of the patient and response 
to hormone replacement.  Hormone deficiencies can 
improve, although corticotroph function seems to be 
the least likely to recover.14  Many doctors recommend 
close monitoring for hormone abnormalities in patients 
receiving ipilimumab, especially after the third infusion.
KEy PoInTS
Hypophysitis is a well recognized side effect of 
ipilimumab therapy.  A high clinical suspicion for hypopi-
tuitarism in patients receiving the drug is imperative 
due to the non-specific symptoms and potentially 
life threatening consequences.  Corticosteroids 
should be promptly initiated as soon as secondary 
adrenal insufficiency is detected.  While ipilimumab 
has many side effects, the drug has improved survival 
in metastatic melanoma and remains an important 
treatment option. 
and a subsequent cosyntropin stimulation test with 250 µg 
of cosyntropin resulted in cortisol values of 5.4 mcg/dL 
and 8.8 mcg/dL at one hour and two hours respectively. 
An a magnetic resonance image (MRI) of the brain with 
and without contrast performed two days earlier for 
surveillance of his known brain metastases was reviewed 
on admission and revealed diffuse enlargement of the 
pituitary gland (Figure 1).  This finding was new compared 
to an MRI performed three months earlier, prior to 
starting ipilimumab (Figure 2).  The patient had no family 
history of endocrine disorders.
dISCuSSIon
Endocrine-related adverse events were reported in 8.5% 
of patients in a recent phase III trial designed to evaluate 
ipilimumab as an adjuvant therapy following resected 
stage III melanoma, with hypophysitis encompassing 
5.1% of these events.8  The majority of patients who 
develop hypopituitarism do so after the third or fourth 
dose of ipilimumab, suggesting a possible cumulative 
effect.1,3  Adverse events have limited the duration of 
use of the drug in patients who could have clinical 
benefit from additional therapy.
The mechanism of hypopituitarism is likely from 
ipilimumab’s immunomodulatory effect on activating 
T-cells, resulting in a lymphocytic hypophysitis.2,3,5,6  It 
has also been shown that some pituitary cells express 
CTLA-4, the receptor target of ipilimumab.9  Therefore, it 
remains unclear whether the adverse effects are caused 
by T-cells acting against antigens shared by tumor cells 
and normal cells or from a direct antibody effect on 
CTLA-4 receptors on pituitary cells, or both.  Presenting 
symptoms are related to a pituitary mass effect and 
consequent hormone deficiencies.5,7,10  Clinical manifes-
tations may be non-specific as they depend on the 
extent of hormone deficiencies.  Additionally, it is 
often difficult to recognize many of these symptoms 
in patients undergoing chemotherapy, but there should 
be a low threshold to consider hypophysitis in a patient 
taking ipilimumab.  Typical symptoms include fatigue, 
headache, and loss of libido.10  Other symptoms 
could include cold intolerance, visual disturbances, 
hypotension, hypoglycemia and hyponatremia.  Our 
patient reported fatigue, but his diagnosis only became 
apparent after hypotension was noted.
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